VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine

Vaccine Information

Vaccine Name: URLC10-TTK-KOC1-VEGFR1-VEGFR2 Multipeptide Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007052
Type: Multipeptide vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
IGF2BP3 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
LY6K gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
VEGFA gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: The peptide vaccine included the 5 peptides as follows; TTK protein kinase (TTK), up-regulated lung cancer 10 (URLC10), insulin-like growth factor–II mRNA binding protein 3 (KOC1), vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2). Each peptide vaccine was mixed with incomplete Freund’s adjuvant (IFA) (Montanide ISA 51; Seppic, Paris, France) separately, and was injected subcutaneously (Iinuma et al., 2014).
Description: This is for Esophageal Cancer (NCT00632333). A cancer vaccine containing five peptide epitopes with potential immunostimulatory and antitumor activity. Peptide epitopes in this vaccine are derived from: URLC10 (up-regulated lung cancer 10), TTK (TTK protein kinase), KOC1 (IGF II mRNA Binding Protein 3) and VEGFRs (vascular endothelial growth factor receptors) 1 and 2. Upon administration, URLC10-TTK-KOC1-VEGFR1-VEGFR2 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, TTK, KCO1, VEGFR 1 and 2 peptides, resulting in cell lysis and decreased tumor growth (Iinuma et al., 2014; NCIT_C74088).

Host Response

References

Iinuma et al., 2014: Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, Horikawa M, Ikeda Y, Matsutani N, Takeda K, Yoshida K, Tsunoda T, Ikeda T, Nakamura Y, Okinaga K. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. Journal of translational medicine. 2014; 12; 84. [PubMed: 24708624].

NCIT_C74088: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C74088]

NCT00632333: Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer [https://clinicaltrials.gov/ct2/show/NCT00632333]